Download GlobalData’s Covid-19 Executive Briefing report
- ECONOMIC IMPACT -
Latest update: 20 October
The global economy is forecast to return to pre-crisis levels by the end of 2021 or early 2022.
The OECD projects the global economy will expand by 5.7% in 2021 and by 4.5% in 2022.
The World Trade Organization forecasts the merchandise trade volume to rise by 10.8% in 2021.
IMF global growth forecasts for 2021 were revised downward by 0.1 percentage points from July forecasts to 5.9%.
Impact of Covid-19 on equity indices
- SECTOR IMPACT: PHARMA -
Latest update: 3 November
Currently, there are 6,093 clinical trials for Covid-19 and promising clinical data continues to emerge for Covid-19 vaccines.
Trial disruption is levelling off, with 1,072 trials still disrupted and 633 pharma/biotech companies and clinical research organisations associated with disrupted trials.
Stalled clinical trials created a work vacuum for clinical research organisations (CROs) and contract development and manufacturing organisations but disrupted trials are slowly starting to resume.
Contract manufacturing organisations (CMOs) and excess capacity contract manufacturers with secure supply lines will benefit from a short-term boost in generic drugs manufacturing needed to treat Covid-19 patients.
Outsourcing partners must deal with issues surrounding a potential excess of client needs upon initiation of future trials, with guidance from regulatory agencies still pending.
Key pharma market developments